Diagnostic and prognostic utility of methylation and protein expression patterns of myopodin in colon cancer

Tumor Biology

Volumn 33, Issue 2, 2012, Pages 337-346

  Esteban, Sergio ^a   Moya, Patricia ^a   Fernandez Suarez, Antonio ^b   Vidaurreta, Marta ^c   González Peramato, Pilar ^d   Sánchez Carbayo, Marta ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL ALTO GUADALQUIVIR   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Biomarker; Colon cancer; Immunohistochemistry; Methylation; Myopodin; Tissue array

Indexed keywords

ACTIN BINDING PROTEIN; AZACITIDINE; MYOPODIN; UNCLASSIFIED DRUG; SYNPO2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DRUG MECHANISM; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN METHYLATION; TISSUE MICROARRAY; VALIDATION PROCESS; BIOSYNTHESIS; COLON TUMOR; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; BASE SEQUENCE; COLONIC NEOPLASMS; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84860308010     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0320-8     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. Lancet. 2010;375:1030-47.
3. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135:1079-99.
4. Carmona FJ, Esteller M. Epigenetics of human colon cancer. Mutat Res. 2010;693:53-60.
5. Rashid A, Issa JP. CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology. 2004;127:1578-88.
6. Sánchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer. 2003;89:2172-7.
7. Jordà M, Peinado MA. Methods for DNA methylation analysis and applications in colon cancer. Mutat Res. 2010;693:84-93.
8. Sánchez-Carbayo M. Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer. Clin Chem. 2003;49:23-31.
9. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042-54.
10. EstellerM. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21:5427-40.
11. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010;29:181-206.
12. Cheng YW, Pincas H, Bacolod MD, Schemmann G, Giardina SF, Huang J, Barral S, Idrees K, Khan SA, Zeng Z, Rosenberg S, Notterman DA, Ott J, Paty P, Barany F. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res. 2008;14:6005-13.
13. Weins A, Schwarz K, Faul C, Barisoni L, Linke WA, Mundel P. Differentiation- and stress-dependent nuclear cytoplasmic redistribution of myopodin, a novel actin-bundling protein. J Cell Biol. 2001;155:393-404.
14. Van Impe K, De Corte V, Eichinger L, Bruyneel E, Mareel M, Vandekerckhove J, Gettemans J. The Nucleo-cytoplasmic actinbinding protein CapG lacks a nuclear export sequence present in structurally related proteins. J Biol Chem. 2003;278:17945-52.
15. Faul C, Hüttelmaier S, Oh J, Hachet V, Singer RH, Mundel P. Promotion of import alpha-mediated nuclear import by the phosphorylation- dependent binding of cargo protein to 14-3-3. J Cell Biol. 2005;169:415-24.
16. De Ganck A, Hubert T, Van Impe K, Geelen D, Vandekerckhove J, De Corte V, Gettemans J. A monopartite nuclear localization sequence regulates nuclear targeting of the actin binding protein myopodin. FEBS Lett. 2005;579:6673-80.
17. 2+/ calmodulin-dependent kinase II, and calcineurin regulate the intracellular trafficking of myopodin between the Z-disc and the nucleus of cardiac myocytes. Mol Cell Biol. 2007;27:8215-27.
18. Liang J, Ke G, You W, Peng Z, Lan J, Kalesse M, Tartakoff AM, Kaplan F, Tao T. Interaction between importin 13 and myopodin suggests a nuclear import pathway for myopodin. Mol Cell Biochem. 2008;307:93-100.
19. Lin F, Yu YP, Woods J, Cieply K, Gooding B, Finkelstein P, Dhir R, Krill D, Becich MJ, Michalopoulos G, Finkelstein S, Luo JH. Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers. Am J Pathol. 2001;159:1603-12.
20. Yu YP, Tseng GC, Luo JH. Inactivation of myopodin expression associated with prostate cancer relapse. Urology. 2006;68:578-82.
21. Sanchez-Carbayo M, Schwarz K, Charytonowicz E, Cordon- Cardo C, Mundel P. Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cellcycle dependent and predicts clinical outcome. Oncogene. 2003;22:5298-305.
22. Jing L, Liu L, Yu YP, Dhir R, Acquafondada M, Landsittel D, Cieply K, Wells A, Luo JH. Expression of myopodin induces suppression of tumor growth and metastasis. Am J Pathol. 2004;164:1799-806.
23. Yu YP, Luo JH. Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. Cancer Res. 2006;66:7414-9.
24. Yu YP, Luo JH. Phosphorylation and interaction of myopodin by integrin-link kinase lead to suppression of cell growth and motility in prostate cancer cells. Oncogene. 2011;30:4855-63.
25. Cebrian V, Alvarez M, Aleman A, Palou J, Bellmunt J, Gonzalez- Peramato P, Cordón-Cardo C, García J, Piulats JM, Sánchez- Carbayo M. Discovery of myopodin methylation in bladder cancer. J Pathol. 2008;216:111-9.
26. Alvarez-Múgica M, Cebrian V, Fernández-Gómez JM, Fresno F, Escaf S, Sánchez-Carbayo M. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. J Urol. 2010;184:1507-13.
27. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60:397-411.
28. Puppa G, Sonzogni A, Colombari R, Pelosi G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Patol Lab Med. 2010;134:837-52.
29. Dawson-Saunders B, Trapp RG. Basic & clinical biostatistics. 2nd ed. Norwalk: Appleton & Lange; 1994.
30. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43:1348-60.
31. De Ganck A, De Corte V, Staes A, Gevaert K, Vandekerckhove J, Gettemans J. Multiple isoforms of the tumor suppressor myopodin are simultaneously transcribed in cancer cells. Biochem Biophys Res Commun. 2008;370:269-73.